Binding Site supports Myeloma Action Month

Myeloma Action Month, held every year in March, aims to increase awareness and understanding of Multiple Myeloma

Myeloma Action Month marks an essential time to spread knowledge about this serious condition. We are excited to announce our partnership with the International Myeloma Foundation to promote better understanding of Multiple Myeloma, raise awareness of the disease, its symptoms, and appropriate tests to order can lead to earlier diagnosis and better outcomes for patients.

The theme for this year's Myeloma Action Month is #MyelomaMilestone. This year’s focus is on empowering individuals to share their personal milestones in the fight against multiple myeloma.

Let’s use this month to educate ourselves and others and contribute to the fight against Multiple Myeloma.

What is Multiple Myeloma?

Multiple Myeloma is a cancer of plasma cells, a type of white blood cell responsible for producing antibodies. Over 180,000 new cases of Multiple Myeloma are diagnosed worldwide every year¹.

In this disease, cancerous plasma cells accumulate in the bone marrow, crowding out healthy blood cells and affecting blood cell production. Myeloma cells often produce abnormal proteins (monoclonal proteins or M-proteins), which can lead to various complications. These can be used as biomarkers for disease detection and monitoring.

Throughout Myeloma Action Month, we will be sharing information about Multiple Myeloma across our social media channels.

About the International Myeloma Foundation

In 1990, the International Myeloma Foundation (IMF) was founded as the first and largest global foundation specifically focusing on multiple myeloma. The Foundation's impact extends to over 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life for myeloma patients while working towards prevention and a cure by focusing on research, education, support, and advocacy. They have organized over 250 educational seminars globally, operates the world-renowned InfoLine, and, in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients.

For more information about the IMF and their work, please visit their website myeloma.org.

Binding Site, part of Thermo Fisher Scientific, is proud to take part in this initiative.